Core Viewpoint - Jingtai Holdings (02228) has seen a significant increase in stock price, rising over 40% in the month, with a current price of HKD 13.75 and a trading volume of HKD 819 million [1] Group 1: Company Developments - On January 7, Jingtai Technology announced that its incubated company, ReviR Technology, received clinical trial approval from the National Medical Products Administration for its small molecule drug RTX-117, which is set to begin Phase I clinical trials in Q1 2026 [1] - RTX-117 is the first Class I innovative drug targeting Charcot-Marie-Tooth disease (CMT) in China and is the first project to enter clinical trials from a series of rare disease drug pipelines developed through AI and robotic-assisted research in collaboration with ReviR [1] Group 2: Market Analysis - Guolian Minsheng Securities (601456) released a report stating that Jingtai Holdings has established a competitive edge in the AI pharmaceutical sector through its software and hardware technology accumulation, platform-based business model, and strategic positioning in key market segments [1] - The approval of RTX-117 for clinical trials marks the beginning of the value realization phase for its technology platform, with expectations for continued expansion of collaborative pipelines, leading to significant performance elasticity and valuation reconfiguration potential [1]
晶泰控股再涨超6% RTX-117临床获批 晶泰控股AI平台价值进一步验证